Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model

被引:415
|
作者
Abrey, Lauren E.
Ben-Porat, Leah
Panageas, Katherine S.
Yahalom, Joachim
Berkey, Brian
Curran, Walter
Schultz, Christopher
Leibel, Steven
Nelson, Diana
Mehta, Minesh
DeAngelis, Lisa M.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[4] Radiat Therapy Oncol Grp, Philadelphia, PA USA
[5] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[6] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
[7] Stanford Comprehens Canc Ctr, Stanford, CA USA
[8] Mayo Clin, Div Radiat Oncol, Rochester, MN USA
关键词
D O I
10.1200/JCO.2006.08.2941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that could be applied to the care of patients and the design of prospective clinical trials. Patients and Methods Three hundred thirty-eight consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between 1983 and 2003 were analyzed. Standard univariate and multivariate analyses were performed. In addition, a formal cut point analysis was used to determine the most statistically significant cut point for age. Recursive partitioning analysis (RPA) was used to create independent prognostic classes. An external validation set obtained from three prospective Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classification. Results Age and performance status were the only variables identified on standard multivariate analysis. Cut point analysis of age determined that patients age <= 50 years had significantly improved outcome compared with older patients. RPA of 282 patients identified three distinct prognostic classes: class 1 (patients <50 years), class 2 (patients >= 50; Karnofsky performance score [KPS] >= 70) and class 3 (patients >= 50; KPS <70). These three classes significantly distinguished outcome with regard to both overall and failure-free survival. Analysis of the RTOG data set confirmed the validity of this classification. Conclusion The MSKCC prognostic score is a simple, statistically powerful model with universal applicability to patients with newly diagnosed PCNSL. We recommend that it be adopted for the management of newly diagnosed patients and incorporated into the design of prospective clinical trials.
引用
收藏
页码:5711 / 5715
页数:5
相关论文
共 50 条
  • [1] Characteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma The Memorial Sloan-Kettering Cancer Center Experience
    Ney, Douglas E.
    Reiner, Anne S.
    Panageas, Katherine S.
    Brown, Hayley S.
    DeAngelis, Lisa M.
    Abrey, Lauren E.
    [J]. CANCER, 2010, 116 (19) : 4605 - 4612
  • [2] OUTCOME OF THE OLDEST OLD WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC)
    Welch, Mary R.
    Omuro, Antonio
    DeAngelis, Lisa M.
    [J]. NEURO-ONCOLOGY, 2011, 13 : 59 - 59
  • [3] Neuroblastoma metastatic to the central nervous system - The Memorial Sloan-Kettering Cancer Center experience and a literature review
    Kramer, K
    Kushner, B
    Heller, G
    Cheung, NKV
    [J]. CANCER, 2001, 91 (08) : 1510 - 1519
  • [4] Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center
    Cherian, Seena
    Modelevsky, Lisa
    Reiner, Anne S.
    Grommes, Christian
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1194 - 1197
  • [5] Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
    Welch, Mary R.
    Omuro, Antonio
    DeAngelis, Lisa M.
    [J]. NEURO-ONCOLOGY, 2012, 14 (10) : 1304 - 1311
  • [6] The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center
    Cassileth, BR
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 585 - 588
  • [7] Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience
    Rocha, Flavio G.
    Matsuo, Kenichi
    Blumgart, Leslie H.
    Jarnagin, William R.
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (04) : 490 - 496
  • [8] Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC).
    Morikawa, Aki
    Diab, Adi
    Patil, Sujata
    Forte, Victoria
    Blum, Brian
    Young, Robert J.
    Beal, Kathryn
    Hudis, Clifford
    Seidman, Andrew David
    McArthur, Heather L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [9] Sequential adjuvant therapy: The Memorial Sloan-Kettering Cancer Center experience
    Hudis, C
    Seidman, A
    Raptis, G
    Fennelly, D
    Gilewski, T
    Baselga, J
    Theodoulou, M
    Sklarin, N
    Moynahan, M
    Surbone, A
    Currie, V
    Lebwohl, D
    Uhlenhopp, M
    Crown, J
    Norton, L
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (01) : 58 - 64